Can-Fite BioPharma Statistics

Total Valuation

Can-Fite BioPharma has a market cap or net worth of ILS 55.19 million. The enterprise value is 37.60 million.

Market Cap	55.19M
Enterprise Value	37.60M

Important Dates

The next estimated earnings date is Thursday, November 28, 2024.

Earnings Date	Nov 28, 2024
Ex-Dividend Date	n/a

Share Statistics

Can-Fite BioPharma has 2.04 billion shares outstanding. The number of shares has increased by 57.39% in one year.

Current Share Class	n/a
Shares Outstanding	2.04B
Shares Change (YoY)	+57.39%
Shares Change (QoQ)	n/a
Owned by Insiders (%)	0.02%
Owned by Institutions (%)	1.79%
Float	1.85B

Valuation Ratios

PE Ratio	n/a
Forward PE	n/a
PS Ratio	17.07
PB Ratio	4.84
P/TBV Ratio	n/a
P/FCF Ratio	n/a
P/OCF Ratio	n/a
PEG Ratio	n/a

Financial Ratio History

Enterprise Valuation

EV / Earnings	-1.35
EV / Sales	14.97
EV / EBITDA	n/a
EV / EBIT	n/a
EV / FCF	-1.34

Financial Position

The company has a current ratio of 2.93, with a Debt / Equity ratio of 0.02.

Current Ratio	2.93
Quick Ratio	2.38
Debt / Equity	0.02
Debt / EBITDA	n/a
Debt / FCF	-0.01
Interest Coverage	n/a

Financial Efficiency

Return on equity (ROE) is -157.62% and return on invested capital (ROIC) is -102.80%.

Return on Equity (ROE)	-157.62%
Return on Assets (ROA)	-57.46%
Return on Capital (ROIC)	-102.80%
Revenue Per Employee	313,915
Profits Per Employee	-3.47M
Employee Count	8
Asset Turnover	0.08
Inventory Turnover	n/a

Taxes

Income Tax	n/a
Effective Tax Rate	n/a

Stock Price Statistics

The stock price has increased by +3.85% in the last 52 weeks. The beta is 0.61, so Can-Fite BioPharma's price volatility has been lower than the market average.

Beta (5Y)	0.61
52-Week Price Change	+3.85%
50-Day Moving Average	2.85
200-Day Moving Average	2.95
Relative Strength Index (RSI)	32.27
Average Volume (20 Days)	8,662,762

Short Selling Information

Short Interest	n/a
Short Previous Month	n/a
Short % of Shares Out	n/a
Short % of Float	n/a
Short Ratio (days to cover)	n/a

Income Statement

In the last 12 months, Can-Fite BioPharma had revenue of ILS 2.51 million and -27.75 million in losses. Loss per share was -0.02.

Revenue	2.51M
Gross Profit	2.51M
Operating Income	-29.34M
Pretax Income	-27.75M
Net Income	-27.75M
EBITDA	-29.31M
EBIT	-29.34M
Loss Per Share	-0.02

Full Income Statement

Balance Sheet

The company has 17.80 million in cash and 214,611 in debt, giving a net cash position of 17.59 million or 0.01 per share.

Cash & Cash Equivalents	17.80M
Total Debt	214,611
Net Cash	17.59M
Net Cash Per Share	0.01
Equity (Book Value)	9.33M
Book Value Per Share	0.01
Working Capital	14.46M

Full Balance Sheet

Cash Flow

In the last 12 months, operating cash flow was -27.98 million and capital expenditures -15,060, giving a free cash flow of -27.99 million.

Operating Cash Flow	-27.98M
Capital Expenditures	-15,060
Free Cash Flow	-27.99M
FCF Per Share	-0.01

Full Cash Flow Statement

Margins

Gross Margin	100.00%
Operating Margin	-1,168.37%
Pretax Margin	-1,105.10%
Profit Margin	n/a
EBITDA Margin	n/a
EBIT Margin	n/a
FCF Margin	-1,114.69%

Dividends & Yields

Can-Fite BioPharma does not appear to pay any dividends at this time.

Dividend Per Share	n/a
Dividend Yield	n/a
Dividend Growth (YoY)	n/a
Years of Dividend Growth	n/a
Payout Ratio	n/a
Buyback Yield	-57.39%
Shareholder Yield	-57.39%
Earnings Yield	n/a
FCF Yield	n/a

Stock Splits

The last stock split was on May 12, 2013. It was a reverse split with a ratio of 0.04.

Last Split Date	May 12, 2013
Split Type	Reverse
Split Ratio	0.04

Scores

Can-Fite BioPharma has an Altman Z-Score of -40.01. A Z-score under 3 suggests an increased risk of bankruptcy.

Altman Z-Score	-40.01
Piotroski F-Score	n/a